Abstract:BACKGROUND:Ovarian cancer is a common malignancy in the female reproductive system with a high mortality rate. The most important reason is multidrug resistance (MDR) of cancer chemotherapy. To reduce side effects, reverse resistance and improve efficacy for the treatment of ovarian cancer, a "core-shell" polymeric nanoparticle-mediated curcumin and paclitaxel co-delivery platform was designed.METHODS:Nuclear magnetic resonance confirmed the successful grafting of polyethylenimine (PEI) and stearic acid (SA) (PEI-SA), which is designed as a mother core for transport carrier. Then, PEI-SA was modified with hyaluronic acid (HA) and physicochemical properties were examined. To understand the regulatory mechanism of resistance and measure the anti-tumor efficacy of the treatments, cytotoxicity assay, cellular uptake, P-glycoprotein (P-gp) expression and migration experiment of ovarian cancer cells were performed. In addition, adverse reactions of nanoformulation to the reproductive system were examined.RESULTS:HA-modified drug-loaded PEI-SA had a narrow size of about 189 nm in diameters, and the particle size was suitable for endocytosis. The nanocarrier could target specifically to CD44 receptor on the ovarian cancer cell membrane. Co-delivery of curcumin and paclitaxel by the nanocarriers exerts synergistic anti-ovarian cancer effects on chemosensitive human ovarian cancer cells (SKOV3) and multi-drug resistant variant (SKOV3-TR30) in vitro, and it also shows a good anti-tumor effect in ovarian tumor-bearing nude mice. The mechanism of reversing drug resistance may be that the nanoparticles inhibit the efflux of P-gp, inhibit the migration of tumor cells, and curcumin synergistically reverses the resistance of PTX to increase antitumor activity. It is worth noting that the treatment did not cause significant toxicity to the uterus and ovaries with the observation of macroscopic and microscopic.CONCLUSION:This special structure of targeting nanoparticles co-delivery with the curcumin and paclitaxel can increase the anti-tumor efficacy without increasing the adverse reactions as a promising strategy for therapy ovarian cancer.

Follicle-stimulating Hormone Polypeptide Modified Nanoparticle Drug Delivery System in the Treatment of Lymphatic Metastasis During Ovarian Carcinoma Therapy.

Data from Follicle-Stimulating Hormone Peptide Can Facilitate Paclitaxel Nanoparticles to Target Ovarian Carcinoma <i>in Vivo</i>

Enhanced EPR Effects by Tumour Stromal Cell Mimicking Nanoplatform on Invasive Pituitary Adenoma

Co-Delivery of Curcumin and Paclitaxel by "Core-Shell" Targeting Amphiphilic Copolymer to Reverse Resistance in the Treatment of Ovarian Cancer.

Tumor-Targeting Polycaprolactone Nanoparticles with Codelivery of Paclitaxel and IR780 for Combinational Therapy of Drug-Resistant Ovarian Cancer

Targeted paclitaxel nanoparticles modified with follicle-stimulating hormone β 81-95 peptide show effective antitumor activity against ovarian carcinoma.

[Preparation and in Vitro Targeting of Follicle Stimulating Hormone Polypeptide Modified Nanoparticles].

Development And Evaluation Of A Novel Tpgs-Mediated Paclitaxel-Loaded Plga-Mpeg Nanoparticle For The Treatment Of Ovarian Cancer

Multifunctional Nanoparticles Encapsulating Astragalus Polysaccharide and Gold Nanorods in Combination with Focused Ultrasound for the Treatment of Breast Cancer

Paclitaxel Nanoparticle Inhibits Growth of Ovarian Cancer Xenografts and Enhances Lymphatic Targeting.

Dually Active Targeting Nanomedicines Based on a Direct Conjugate of Two Purely Natural Ligands for Potent Chemotherapy of Ovarian Tumors

Retro-inverso follicle-stimulating hormone peptide-mediated polyethylenimine complexes for targeted ovarian cancer gene therapy.

Octreotide modified liposomes that co-deliver paclitaxel and neferine effectively inhibit ovarian cancer metastasis by specifically binding to the SSTR2 receptors

The Inhibitory Effect of Paclitaxel Nanoparticles on Ovarian Cancer Xenografts and Lymphatic Targeting

Mesothelin-Mediated Paclitaxel Phase-Shifted Nanodelivery System for Molecular Ultrasound Imaging and Targeted Therapy Potential in Ovarian Cancer

Follicle-stimulating hormone peptide-conjugated nanoparticles for targeted shRNA delivery lead to effective gro-α silencing and antitumor activity against ovarian cancer

Specific Cell Targeting with APRPG Conjugated PEG–PLGA Nanoparticles for Treating Ovarian Cancer

Enhanced antitumor effects of follicle-stimulating hormone receptor-mediated hexokinase-2 depletion on ovarian cancer mediated by a shift in glucose metabolism

Folate Functionalized Ph-Sensitive Nanoparticulate System to Decrease the Toxicity and Enhance the Anti-Cancer Activity of Pirarubicin for Lymphoma Therapy Via Downregulation of H3K18la and H3K9la

Enhancing Targeted Therapy in Hepatocellular Carcinoma Through a Ph-Responsive Delivery System: Folic Acid-Modified Polydopamine-Paclitaxel-Loaded Poly(3-hydroxybutyrate-co-3-hydroxyvalerate) Nanoparticles.

Nanoparticle-Based Combination Therapy for Ovarian Cancer